ライフサイエンスコーパス: praziquantel

1 incipally the safe and relatively cheap drug praziquantel.

2 d patients was followed by chemotherapy with praziquantel.

3 mass treatment with the only available drug, praziquantel.

4 received between 1 and 9 rounds of MDA with praziquantel.

5 s before and 25-27 days after treatment with praziquantel.

6 s predominantly on the use of a single drug, praziquantel.

7 d mice treated with the antischistosome drug praziquantel.

8 aths annually, depends almost exclusively on praziquantel.

9 facturers, and the reduced price of the drug praziquantel.

10 histosoma mansoni and HIV-1 was treated with praziquantel.

11 azole (odds ratio 0.70, 95% CI 0.35-1.42) or praziquantel (0.60, 0.29-1.23) treatment.

12 All group 1 patients were treated with praziquantel; 1 patient with myeloradiculopathy also rec

13 e assessed a 5-year treatment programme with praziquantel (40 mg/kg per treatment) against schistosom

14 ing system, represented by the antihelmintic praziquantel, 8.

15 Praziquantel, administered at a single 40 mg/kg dose in

16 aneous treatment of coinfected children with praziquantel and albendazole affected schistosome- and h

17 d disability averted with integrated MDA (of praziquantel and albendazole) for schistosomiasis and so

18 WHO guidelines to integrated treatment (both praziquantel and albendazole).

19 ziquantel-matching placebo (n=625), 40 mg/kg praziquantel and an albendazole-matching placebo (n=626)

20 The search for alternatives to praziquantel and other tools for control of schistosomia

21 ew strategies for potentiating the action of praziquantel and possibly overcoming drug resistance.

22 be six times higher than WHO guidelines for praziquantel and two times higher for albendazole.

23 elated immune responses after treatment with praziquantel and whether the development of these immune

24 ected individuals 1 month posttreatment with praziquantel, and antibody responses were measured using

25 Millions of people are treated annually with praziquantel, and drug-resistant parasites thus are like

26 tively with albendazole and selectively with praziquantel, and monitored for 6 months.

27 Sj67, measured 4 weeks after treatment with Praziquantel, and resistance to reinfection in a populat

28 ther empiric albendazole every 3 months plus praziquantel annually (treatment group) or to standard c

29 Single-dose praziquantel appears to be as efficacious as the standar

30 increase in viral load after treatment with praziquantel are unclear, these results do not support t

31 -30 years old, all of whom were treated with praziquantel at baseline.

32 -infection studies in humans have shown that praziquantel can have long-term effects beyond a transie

33 mass administration with a single chemical, praziquantel, carries the risk that drug resistance will

34 Treatment with praziquantel did not have a significant effect on birthw

35 es are more likely to be exposed not only to praziquantel directly but also to hosts with altered imm

36 addition, studies that address the safety of praziquantel during pregnancy could lead to further adop

37 had ERRs below the 90% threshold of optimal praziquantel efficacy set by the World Health Organizati

38 and after the large-scale administration of praziquantel for schistosomiasis and albendazole for soi

39 the development of an appropriate paediatric praziquantel formulation, and present blocks are identif

40 e reactions occurred in five patients in the praziquantel group and two in the placebo group, and inc

41 group (184 to the placebo group, 186 to the praziquantel group).

42 dependent on the continued high efficacy of praziquantel; however, drug efficacy is rarely monitored

43 The reduced efficacy of praziquantel in schools with a higher exposure to MDA ma

44 efforts to expand the use of cheap, generic, praziquantel in sub-Saharan Africa.

45 As mass drug administration with praziquantel increases in an attempt to transition from

46 flux measurements of a fluorescent analog of praziquantel indicate that it is also a substrate for SM

47 creased by multiple rounds of infections and praziquantel-induced cures.

48 ministration (MDA) programmes using the drug praziquantel is resulting in substantial increases in th

49 ounting evidence showing that treatment with praziquantel is safe, beneficial, and could be delivered

50 Mass drug administration (MDA) with praziquantel is the cornerstone of schistosomiasis contr

51 No vaccine is available, and only one drug (praziquantel) is used against the parasite.

52 tions to offer pregnant women treatment with praziquantel, many nations continue to withhold treatmen

53 aziquantel (n=628), 440 mg albendazole and a praziquantel-matching placebo (n=625), 40 mg/kg praziqua

54 626), or an albendazole-matching placebo and praziquantel-matching placebo (n=628).

55 patients to 440 mg albendazole and 40 mg/kg praziquantel (n=628), 440 mg albendazole and a praziquan

56 tors and to calculate the number of doses of praziquantel needed for prevention of morbidity.

57 The numbers of doses of praziquantel needed per year were estimated to be 123 mi

58 chistosomiasis has demonstrated an impact of praziquantel on hemoglobin concentration.

59 ction with S. japonicum after treatment with praziquantel on the mean hemoglobin level, iron-deficien

60 0 mg/kg, 40 mg/kg, 50 mg/kg, or 3 x 25 mg/kg praziquantel or placebo.

61 eneration to show that the isoquinoline drug praziquantel (PZQ) acts as a small molecule neurogenic t

62 overage of community-directed treatment with praziquantel (PZQ) and albendazole (ALB) was analyzed in

63 chistosoma japonicum-infected Filipinos with praziquantel (PZQ) and performed ultrasound to quantify

64 m antigen (SWA), or Teg after treatment with praziquantel (PZQ) in a cohort of 187 individuals living

65 sticercosis with either albendazole (ABZ) or praziquantel (PZQ) is suboptimal.

66 Regular treatment with praziquantel (PZQ) is the strategy for human schistosomi

67 ould not effectively clear adult worms after praziquantel (PZQ) treatment and suffered increased morb

68 nyl derivatives of the antischistosomal drug praziquantel (PZQ) with the formula (eta(6)-PZQ)Cr(CO)3

69 l-known drug against schistosomiasis, namely praziquantel (PZQ), are reported.

70 The treatment relies on a single drug, praziquantel (PZQ), making the discovery of new compound

71 nt drug of choice against schistosomiasis is praziquantel (PZQ), which has minimal side effects and i

72 Schistosomiasis is treated with the drug praziquantel (PZQ), which has proved the therapeutic mai

73 such responses increase after treatment with praziquantel (PZQ).

74 Current treatment depends on a single agent, praziquantel, raising concerns of emergence of resistant

75 schistosomiasis is effectively treated with Praziquantel, rapid reinfection with rebound morbidity p

76 By the mid-1980s, the effective oral drug, praziquantel, replaced tartar emetic a s treatment f o r

77 programmes on the development and spread of praziquantel resistance is uncertain, but this possibili

78 Despite the limited reports of praziquantel resistance, the relative success of chemoth

79 rces the need for monitoring the spectrum of praziquantel sensitivity of schistosome populations and

80 dicate the inadequacy of current niclosamide-praziquantel strategies alone to achieve sustainable int

81 globin was observed in children who received praziquantel, strongly supporting population-based mass

82 IC(50)=12.1 muM) and nifedipine, and also by praziquantel, the current drug of choice against schisot

83 istosoma mansoni with reduced sensitivity to praziquantel, the drug currently used to treat this negl

84 ch earlier changes in immune reactions after praziquantel therapy in Schistosoma mansoni-infected fis

85 ealth education (WSH) with administration of praziquantel to school-aged children.

86 15 weeks postinfection, one group was given praziquantel to treat schistosomiasis infection.

87 y 1 or 2 years with the isoquinolinone drug, praziquantel, to suppress morbidity.

88 ed (1:1) to receive either over-encapsulated praziquantel (total dose 60 mg/kg given as two split dos

89 Praziquantel-treated children had more nausea, abdominal

90 0.96-1.16], pneumonia [1.11, 0.90-1.38]) or praziquantel treatment (malaria [1.00, 0.84-1.20], diarr

91 nes elicited by 3 schistosome to examine how praziquantel treatment alters immune polarization and wh

92 Praziquantel treatment for Schistosoma mansoni infection

93 from 92.7% to 95.5% and ERRs >99.5% for all praziquantel treatment groups.

94 Posttreatment results are consistent with praziquantel treatment inducing quantitative and qualita

95 Praziquantel treatment markedly alters polarization of s

96 chistosoma spp and of the number of doses of praziquantel treatment needed to prevent morbidity at di

97 Praziquantel treatment not only cures infection but also

98 chronic S. mansoni infection with or without praziquantel treatment survived malaria, compared to onl

99 and cercaria antigens pre- and 6 weeks post-praziquantel treatment.

100 n in children who received only the baseline praziquantel treatment.

101 xposed individuals before and after curative praziquantel treatment.

102 Neither albendazole nor praziquantel treatments affected infant response to BCG,

103 and CD23(+) B cells after receiving > or =3 praziquantel treatments over the course of follow-up.

104 concurrent administration of albendazole and praziquantel was conducted in>1500 children with high pr

105 r S. mansoni every 4 months and treated with praziquantel when positive (arm A; n=68) or were tested

106 The interaction of praziquantel with SMDR2 may offer new strategies for pot